Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JP
NCT00144547 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 241
Last updated 2013-08-09
Summary
This is an open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with RA who participated in Study MRA012JP.
Conditions
Interventions
- DRUG
-
MRA(Tocilizumab)
8mg/kg(i.v.)/4weeks
Sponsors & Collaborators
-
Chugai Pharmaceutical
lead INDUSTRY
Principal Investigators
-
Takahiro Kakehi · Chugai Pharmaceutical
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-04-30
- Primary Completion
- 2008-08-31
- Completion
- 2009-06-30
More Related Trials
-
PhaseⅢOpen-label Study of MRA for Rheumatoid Arthritis(RA)
NCT00380601 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)
NCT00144625 ·Status: COMPLETED ·Phase: PHASE3
-
Comparative Study (Double-Blind) of MRA for Rheumatoid Arthritis (RA)
NCT00144521 ·Status: COMPLETED ·Phase: PHASE3
-
Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)
NCT00144560 ·Status: COMPLETED ·Phase: NA
-
Clinical Pharmacology Study of MRA in Patient With Rheumatoid Arthritis (RA) With Renal Impairment
NCT00144573 ·Status: COMPLETED ·Phase: NA
-
Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)
NCT00144664 ·Status: COMPLETED ·Phase: PHASE3
-
Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
NCT00144599 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.)
NCT00661284 ·Status: COMPLETED
-
An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies
NCT00720798 ·Status: COMPLETED ·Phase: PHASE3
-
Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients
NCT01347983 ·Status: COMPLETED ·Phase: PHASE3
-
A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis
NCT00721123 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
NCT01332994 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of TJ003234 in Rheumatoid Arthritis Patients
NCT04457856 ·Status: UNKNOWN ·Phase: PHASE1
-
Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis
NCT02404558 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate
NCT00845832 ·Status: TERMINATED ·Phase: PHASE2
-
Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis
NCT00074438 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients
NCT00850343 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.
NCT00503425 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy
NCT00468546 ·Status: COMPLETED ·Phase: PHASE3
-
A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis
NCT06887127 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents.
NCT00504777 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis
NCT01214733 ·Status: COMPLETED ·Phase: PHASE3
-
The Safety and Effectiveness of Tocilizumab in Rheumatoid Arthritis
NCT04384068 ·Status: UNKNOWN
-
Efficacy and Safety Study of MP-435 in Combination With Methotrexate (MTX) in Patients With Rheumatoid Arthritis
NCT01143337 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients
NCT01258712 ·Status: COMPLETED ·Phase: PHASE3